ERBB2 and neoplasm: This suggests that HER2 IHC scoring may not fully account for tumor heterogeneity and that molecular subtyping may have additional value to HER2 IHC scoring for prediction of pCR after neoadjuvant treatment with chemotherapy and HER2-blockade.